neogen-biotech Aktie mit Gewinnen! - 500 Beiträge pro Seite

[knoxi]

neogen mit einem KGV für 2000 von 22! Siehe Onvista. Laut Forbes-Börsenzeitschrift ,eines
von den besten "200 best Small Companiesof Americs"!
Nachzulesen bei quicken.com----- Sparte "news"
Meines Erachtens bin ich bei dieser Firma ganz am Anfang des Kurses dabei! Genaue Beschreibung hat User "Fortsch" geliefert. Betrachtung lohnt sich auf jedenfall! Nasdaq Kürzel:NEOG
WPKN:883297

[Beaumont]

NEOGEN !!!
Mit der Aktie habe ich trotz Baisse ordentliche Kurssteigerungen zu verbuchen. Lebensmittel-Testverfahren werden ja auch immer aktueller durch BSE, schlechte Nachrichten über Schweinefleisch, etc.
Da ist noch ordentlich was drin....KAUFEN

[Madsen]

Ich hoffe sie sinkt noch ein bißchen,dann steig ich auch ein.
Cutting Edge empfiehlt die Aktie auch zum Kauf.
Habt ihr noch mehr Infos?
Mfg Madsen

[Beaumont]

Guten Tag Madson,
unter www.neogen.com findest Du das Unternehmen in Englisch.

[Wunram]

Neogen Continues Surge With Second Quarter Results

LANSING, Mich., Jan. 9 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) today announced a 66% increase in quarterly revenues, and earnings that exceeded analyst expectations.

Neogen`s second quarter revenues jumped to $9,009,000, a 66% increase from last year`s second quarter of $5,425,000. The quarter marked the first time the Company has exceeded the $9 million mark. Year-to-date revenues stand at $17,133,000 -- a 59% increase over the prior year comparable revenues of $10,765,000.

Neogen reported earnings of $0.15 per share for the second quarter, which ended Nov. 30, as compared with $0.06 for the same period last year. Year to date, Neogen`s FY 2001 earnings are $0.27 per share, as compared to $0.19 for the first six months of last year.

"Neogen has shown increases in revenue for 36 of the past 40 quarters compared to the year earlier," said James Herbert, Neogen`s president. "Our operating profits for the first half of this year were more than double last year`s. These continued results keep us excited about Neogen`s future."

Neogen`s 66% quarterly revenue increase was led by its Animal Safety Division, with a jump of 83% from the previous fiscal year. Of the Animal Safety increase, 28% can be attributed to the sales of comparable products from year to year, and the remainder to second-quarter sales of the recently acquired AmVet and Squire product lines. Year to date, Animal Safety sales are up 61%.

Food Safety Division quarterly revenues were up 51% on a quarter-to- quarter comparison, and 58% for FY 2001`s first six months. The increase is attributed to higher sales in the Company`s diagnostic test kits and the February 2000 acquisition of dehydrated culture media manufacturer Acumedia.

Food Safety sales were led by the strong 39% growth in sales of test kits to detect dangerous bacteria, including E. coli O157:H7, Salmonella and Listeria. Year to date, sales of the test kits for pathogens have increased 68% from the previous year.

"It was obviously an outstanding quarter that we think will lead to an outstanding year," said Richard Current, Neogen`s chief financial officer. "Our sales and marketing, and general and administrative expenses, decreased as a percentage of sales as we continue to leverage those costs against expanding product offerings."

In the second quarter, Neogen was named to Forbes Magazine`s 200 Best Small Companies in America. In making the announcement of this year`s list, Forbes` editors stated that the companies on the list represent good growth and value candidates for investors. "With earnings warnings becoming nearly a daily event, investors are hungry for time-tested winners like these," said Forbes` editors.

Neogen also added to its comprehensive line of diagnostic test kit products in the second quarter. The additions included Agri-Screen(R) for Cry9C, which detects the unique protein in StarLink(R) corn, and Agri-Screen for Bacillus thuringiensis (Bt), which detects proteins used in genetic modification for insect resistance. StarLink corn was not approved for human consumption, and prompted numerous recalls when it found its way into food. These new tests are in the same format as Neogen`s popular and trusted tests to detect toxins in grain.

Also new to Neogen`s offerings is Veratox(R) for Capsaicin, a quantitative test that provides the spice industry with a quicker, less expensive alternative to methods currently used. Capsaicin is the compound that gives peppers their hotness.

In October, Neogen`s Board of Directors increased its authorization for Company common stock repurchase from the previously announced 750,000 shares to 1 million shares. Neogen has repurchased 627,000 shares since its repurchase program began. Currently, there are about 5,680,000 outstanding shares of Company common stock. Neogen has not repurchased shares in the past several weeks, but Company management stated that the repurchase program would continue at a pace determined by market conditions.

Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company`s Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen`s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements and wound care products.


NEOGEN CORPORATION CONSOLIDATED STATEMENT OF OPERATIONS
(In thousands, except for per share data)

Quarter ended Nov. 30
2000 1999
Revenue $9,009 $5,425
Gross Margin 4,544 2,972
Operating Income 1,160 258
Net Income 860 338
Net Income Per Share $0.15 $0.06

Six months ended Nov. 30
2000 1999
Revenue $17,133 $10,765
Gross Margin 8,540 6,051
Operating Income 1,962 936
Net Income 1,532 1,146
Net Income Per Share $0.27 $0.19


Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


/CONTACT: Richard R. Current, Vice President & CFO of Neogen Corporation, 517-372-9200/

[Wunram]

Neogen Unveils Test for Salmonella enteritidis With Regulation Pending

LANSING, Mich., Feb. 13 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) today announced the introduction of a kit for the leading cause of gastroenteritis, just in time to aid food producers comply with pending governmental regulation.

Neogen`s new test kit, Reveal(R) for Salmonella enteritidis (Se), provides commercial egg producers with a quick and easy method of detecting the dangerous pathogen, as the U.S. Food and Drug Administration prepares to implement Se-reduction regulations. Se became the leading cause of salmonellosis in the U.S. in 1994. The foodborne illness caused by Se is generally due to eating raw, incompletely cooked, or recontaminated eggs. Ingestion of Se-contaminated poultry meat is the second leading cause of this illness.

"The introduction of Reveal for Se will be an invaluable tool to egg producers, as they comply with the FDA`s final rule, and seek to further reduce the likelihood of Se-contaminated eggs reaching consumers," said Dr. Joseph Madden, Neogen`s vice president of scientific affairs. "Until the introduction of an effective rapid test for Se, the industry had to wait up to 7 days for an outside laboratory`s test results. Reveal for Se enables the industry to get results within 24 hours -- it provides the rapid, accurate answer they need to manage their flocks and egg production."

In December 1999, the President`s Council on Food Safety released a plan to eliminate Se-related illnesses due to eggs. The plan`s first objective is to reduce the number of Se-containing eggs marketed by requiring the testing of all commercial egg-laying chicken flocks for Se. In response to the council`s recommendation, the FDA is expected to publish and implement a final rule this year.

Neogen`s Se test is based upon antibodies developed by Neogen and the USDA at the Russell Center in Athens, Ga. Reveal for Se utilizes unique antibodies to ensure sensitivity and specificity. The test withstood the scrutiny of an intensive third-party validation, and was found to have no cross-reactivity with a wide range of other Salmonella species.

The USDA estimates that as many as 11 eggs per 100,000 are contaminated with Se. According to the USDA, there were approximately 371 million egg layers in the U.S. in January 2001, providing more than 71.4 billion eggs per year. This translates to up to 7,854,000 Se-infected in-shell eggs in the U.S. every year. The effects of salmonellosis can range from mild nausea and diarrhea to severe, and potentially fatal, complications in the very young and old, and among those with weakened immune systems.

Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company`s Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen`s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements and wound care products.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


/CONTACT: Rebecca Hoerner, Microbiology Product Manager of Neogen Corporation, 517-372-9200/

[Wunram]

Neogen to Present at Roth Capital Growth Stock Conference

LANSING, Mich., Feb. 19 /PRNewswire/ -- Neogen Corporation`s (Nasdaq: NEOG) CEO James Herbert and CFO Richard Current will be among the presenters at the Roth Capital Growth Stock Conference, set for today through Wednesday in Dana Point, Calif.

Neogen`s presentation will touch on the company`s 19-year history of potent growth, and highlight Neogen`s solid current financial situation and future growth potential.

In January, Neogen announced second quarter revenues of over $9 million, a 66% increase from the previous year`s second quarter. Revenues were over $17 million for the six months ended on Nov. 30 -- a 59% increase over the prior year. The quarter was Neogen`s 36th of the past 40 when revenues increased as compared to prior years. Second quarter net income was $0.15 per share, as compared with $0.06. Year to date, net income was $0.27 per share, as compared to $0.19.

In October, Neogen was named to Forbes Magazine`s 200 Best Small Companies in America. Forbes` editors stated that the companies on the list represent good growth and value candidates for investors. "With earnings warnings becoming nearly a daily event, investors are hungry for time-tested winners like these," said Forbes` editors.

Neogen`s current financial strength is reflected in its balance sheet as of Nov. 30: cash and securities of nearly $6 million; working capital of over $15 million; and long-term debt of less than $100,000.

The presenters at the Roth conference will provide detailed analysis on why Neogen`s stock remains attractive, including its solid position in the growing markets it serves, consistent growth in sales and net income, and strong financial position.

Neogen develops and markets products and services dedicated to food and animal safety, with revenues about split evenly between two divisions. The company`s Food Safety Division markets test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen`s Animal Safety Division markets veterinary diagnostics, instruments, pharmaceuticals, nutritional supplements and wound care products.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


/CONTACT: Richard R. Current, Vice President & CFO of Neogen Corporation, 517-372-9200/

[Wunram]

USDA Verifies Performance of Neogen`s Rapid Test to Detect StarLink Corn

LANSING, Mich., Feb. 20 /PRNewswire/ -- The performance claims of Neogen Corporation`s (Nasdaq: NEOG) rapid and accurate test to detect StarLink(R) genetically-modified corn have been verified by the USDA`s Grain Inspection, Packers and Stockyards Administration (GIPSA).

GIPSA`s demanding verification process showed that Neogen`s test for StarLink corn, Agri-Screen(R) for Cry9C, can detect 1 kernel of StarLink corn among 800 kernels of non-genetically modified corn at a low expression level of Cry9C in the grain. The detection level equates to detecting StarLink contamination of only 0.125% in a sample.

"The verification provides our customers even more confidence in the proven accuracy of our test kit for StarLink corn," said James Herbert, Neogen`s president. "The verification also allows GIPSA to add the Cry9C test to the list of Neogen`s products the agency relies on to ensure the safety of our nation`s grain supply. Neogen has been the exclusive supplier of the aflatoxin test used by GIPSA every year since 1994 to test corn and other commodities for the dangerous natural toxin."

Neogen`s Agri-Screen for Cry9C is in the same ELISA-based format widely used and accepted by GIPSA for many years, and other grain quality control personnel worldwide.

"In addition to the trust that we have built with many long-term customers since we began developing grain testing products 16 years ago, the ELISA format provides a critical advantage over other StarLink tests on the market," said Chuck Bird, Neogen`s technical services manager. "Our test allows the economical batching of samples, up to 20 at a time -- a huge advantage for regulators and other large testers. Also, the use of a microwell reader, and its numeric results, should help overcome the confused results that have occurred recently with other methods. When processors test for StarLink contamination, they want to be sure."

StarLink corn was approved only for animal feed by the Environmental Protection Agency because of concerns that it could trigger allergic reactions. The maker of StarLink, Aventis CropScience, has stated that it has evidence that StarLink corn does not pose an allergic risk.

Neogen`s new tests are Agri-Screen for Cry9C, which detects the unique protein in StarLink corn, and Agri-Screen for Bacillus thuringiensis (Bt), which detects Cry9C and other proteins used in genetic modification, Cry1Ab and Cry1Ac. Bt is a common soil bacterium which produces proteins that are natural pesticides.

Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company`s Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


/CONTACT: Chuck Bird, Technical Services Manager of Neogen Corporation, 517-372-9200/

[Wunram]

auch sowas kann passieren:

Neogen: Clerical Error Creates False Impression

LANSING, Mich., Feb. 22 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that a clerical error in a filing with the Securities and Exchange Commission created the false impression that Neogen President James Herbert was attempting to sell a large number of shares of company common stock. No such sale of the magnitude reported was initiated by Herbert.

Herbert`s Form 144 filing with the SEC should have proposed to sell 20,200 shares of Neogen common stock to generate $260,000 in cash. With the cash, Herbert exercised his options on 36,100 shares of company stock set to expire.

The form filed with the SEC mistakenly stated that Herbert proposed to sell 200,200 shares of common to generate $260,000 in cash. An amended Form 144 has been filed with the SEC, but has yet to be posted.

"With the transaction, I am actually increasing my holdings in Neogen by about 16,000 shares," Herbert said. "I have total confidence in Neogen`s future, and am increasing my personal stake in Neogen`s continuing success."

With the additional 16,000 shares, Herbert owns about 400,000 shares of Neogen`s approximately 5.7 million shares of common stock.

Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company`s Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen`s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements and wound care products.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


/CONTACT: Richard R. Current, Vice President & CFO of Neogen Corporation, 517-372-9200

[knoxi]

Neogen steigt langsam ,aber stetig!

[puhvogel]

Das ist der beeindruckenste Chart dieer Branche zur Zeit, den ich so kenne.
Neid

[Kelbi]

@puhvogel

Neogen testet gerade die 200 Tage Linie, die Stochastikindikatoren sind total überverkauft, an den fundamentalen Daten hat sich eigetlich nichts geändert, ich denke daran jetzt einzusteigen.

Was denkst Du?